



## Oligonucleotides and Nucleic-Acid-Based Strategies to Address Therapeutic Challenges: From the Bench to the Bedside

Guest Editors:

**Dr. Tina Kauss**

ARNA, Inserm U1212, CNRS 5320,  
University of Bordeaux,  
Bordeaux, France

**Prof. Dr. Philippe Barthélémy**

ChemBioPharm, ARN:  
Régulations Naturelle et  
Artificielle, Université de  
Bordeaux, INSERM U1212, CNRS  
UMR 5320, ARNA, 33076  
Bordeaux, France

Deadline for manuscript  
submissions:

**closed (31 May 2022)**

### Message from the Guest Editors

Dear Colleagues,

The recent pandemic events have demonstrated the importance of alternative strategies to tackle new therapeutic challenges and unmet needs. Oligonucleotides and nucleic-acid-based drugs have appeared as a promising but underused strategy. Whereas the concept of oligonucleotides for therapeutic purposes goes back to the late nineties, several commercialized therapies have made the proof of concept of their therapeutic potential. The rational design and the choice of the type of nucleic acid allows one to optimize the mechanism of action. Chemical modifications and conjugations of nucleic acids confer the prolonged half-life, but also enhanced efficacy, due to better controlled pharmacokinetics and increased specificity while reducing the target effects. The recent success of lipid nanoparticles for nucleic acid delivery has underlined the importance of their formulation. The aim of this Special Issue is to highlight and structure the knowledge available in terms of design strategy, chemistry used, delivery systems and therapeutic applications.

Dr. Tina Kauss  
Prof. Dr. Philippe Barthélémy  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma